Is Now an Ideal Moment to Include Labcorp Shares in Your Investment Portfolio?

Labcorp Holdings Inc.: Growth Prospects and Challenges Ahead

Labcorp Holdings Inc. (LH) is positioned for continued expansion, thanks to its ongoing efforts to broaden its testing services in rapidly advancing fields such as neurology and autoimmune disorders. The company’s commitment to strengthening collaborations with hospitals and healthcare organizations has solidified its footprint in key markets. Additionally, its LaunchPad initiative is contributing to improved profit margins. However, Labcorp faces obstacles from unfavorable currency movements and broader economic uncertainties that could impact its operations.

Over the past year, Labcorp’s stock has climbed 10.2%, outpacing the medical products sector’s 6.4% gain but trailing the S&P 500’s 21.8% surge.

With a market value of $23.61 billion, Labcorp stands out for its 6.2% earnings yield, which surpasses the industry average of 4.1%. The company has also exceeded earnings expectations by an average of 3.07% over the last four quarters.

Key Drivers of Labcorp’s Growth

Expanding in High-Potential Testing Segments

Labcorp is actively growing its presence in specialized diagnostic areas, including oncology, women’s health, autoimmune conditions, and neurology—fields projected to expand at a rate up to three times faster than other therapeutic categories. In cancer diagnostics alone, Labcorp now offers over 450 tests covering a wide range of cancer types and stages, demonstrating its comprehensive capabilities. The acquisition of Invitae has further extended its reach in genetic testing. Notably, Labcorp’s PGDx elio tissue complete has received CE marking under the EU’s new In Vitro Diagnostic Regulation, making it the first test in the region approved for broad solid tumor profiling.

The company has also enhanced its neurology offerings with two new Alzheimer’s disease tests suitable for both specialty and primary care. Labcorp is working with Geneoscopy to increase access to the FDA-cleared ColoSense at-home colorectal cancer screening test.

Image Source: Zacks Investment Research

Strategic Acquisitions and Partnerships

Labcorp has consistently expanded its network by forming alliances with health systems and regional laboratories, thereby increasing its reach among patients and providers. In 2025, the company acquired select oncology and clinical testing assets from BioReference Health and took over the ambulatory outreach laboratory business of North Mississippi Health Services, becoming the referral lab for its seven hospitals and clinics.

During the fourth quarter, Labcorp invested $258 million in acquisitions, which contributed 1.2% to revenue growth. The company finalized the purchase of outreach assets from Community Health Systems, acquired anatomic pathology assets from Incyte Diagnostics, and agreed to acquire outreach laboratory services from Parkview Health.

Enhancing Operational Efficiency

Labcorp’s LaunchPad business improvement program delivered annual savings of $100–$125 million in 2025. The company has introduced AI-driven tools like the Labcorp Test Finder, which streamlines appointment scheduling and results delivery for patients. This tool is now integrated into the Labcorp Diagnostic Assistant, accessible through electronic health records and the Labcorp Link platform.

Additionally, Labcorp rolled out eClaim Assist, a digital solution that simplifies the process of updating and responding to patient claim information, reducing turnaround times and boosting efficiency. For the full year 2025, Labcorp improved its enterprise margin by over 50 basis points, driven by robust revenue growth, disciplined cost control, and LaunchPad synergies.

Challenges Facing Labcorp

Currency Volatility

Labcorp’s significant international operations expose it to currency risks. The recent strengthening of the U.S. dollar, with further increases anticipated, could negatively affect the company’s overseas revenue streams.

Macroeconomic Pressures

Labcorp’s performance is closely tied to demand for diagnostic and drug development services from a range of clients, including patients, healthcare providers, and medical device firms. Recent global economic instability, such as inflation, has dampened demand and affected customers’ ability to pay, putting pressure on the company’s profitability. Ongoing geopolitical tensions and retaliatory tariffs are also straining supply chains and driving up costs.

Labcorp Stock Outlook

In the last month, analysts have slightly raised their consensus estimate for Labcorp’s 2026 earnings per share by 0.3%, now projecting $17.65. Revenue forecasts for 2026 stand at $14.67 billion, representing a 5.2% increase over 2025 estimates.

Other Leading MedTech Stocks

• Phibro Animal Health (PAHC): With an earnings yield of 5.5%, well above the industry’s 2.5%, Phibro has outperformed expectations in each of the last four quarters, averaging a 20.2% surprise. Its shares have soared 117.5% over the past year, even as the industry declined by 15.1%. PAHC currently holds a Zacks Rank #1 (Strong Buy).
• Envista (NVST): Also rated Zacks Rank #1, Envista boasts a 4.8% earnings yield compared to the industry’s 2.5%. The company’s shares have risen 54% year-over-year, and it has beaten earnings estimates in each of the last four quarters, with an average surprise of 16.4%.
• Align Technology (ALGN): Currently holding a Zacks Rank #2 (Buy), Align Technology is projected to achieve a long-term earnings growth rate of 10.1%, outpacing the industry’s 9.1%. Its shares have increased 7.5% over the past year, while the industry grew by 22%. Align exceeded earnings expectations in three of the last four quarters, with an average surprise of 6.2%.

Unlocking the Next Wave of AI Investment

The upcoming surge in artificial intelligence is expected to generate immense opportunities for investors, potentially adding trillions to the global economy and transforming daily life. Early investors in companies like Nvidia have already seen substantial returns.

However, the rapid ascent of the first generation of AI stocks may soon plateau, paving the way for a new group of innovative companies to drive the next phase of exponential growth.

The Zacks report, AI Boom 2.0: The Second Wave, highlights four lesser-known companies that could become leaders in the next stage of AI advancement.